The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor-/progesterone receptor-/HER-2-: Breast carcinomas

被引:129
作者
Verlinden, Lieve
Bempt, Isabelle Vanden
Eelen, Guy
Drijkoningen, Maria
Verlinden, Ilse
Marchal, Kathleen
De Wolf-Peeters, Christiane
Christiaens, Marie-Rose
Michiels, Luc
Bouillon, Roger
Verstuyf, Annernieke
机构
[1] Katholieke Univ Leuven, Lab Expt Geneeskunde & Endocrinol, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven, CMPG ESAT, Louvain, Belgium
[3] Katholieke Univ Leuven, Univ Hosp, Dept Pathol, Louvain, Belgium
[4] Katholieke Univ Leuven, Univ Hosp, Multidisciplinary Breast Ctr, Louvain, Belgium
[5] Katholieke Univ Leuven, Univ Hosp, Dept Surg, Louvain, Belgium
[6] Univ Hasselt, Biomed Res Inst BIOMED, Diepenbeek, Belgium
关键词
D O I
10.1158/0008-5472.CAN-06-3545
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We previously showed that checkpoint kinase 1 (Chk1) and Claspin, two DNA-damage checkpoint proteins, were down-regulated by 1,25-dihydroxyvitamin D-3, a known inhibitor of cell proliferation. In the present study, we aimed to investigate the transcriptional regulation of Chk1 and Claspin and to study their expression levels in human breast cancer tissue. Transient transfection experiments in MCF-7 breast cancer cells showed that promoter activities of Chk1 and Claspin were regulated by the E2F family of transcription factors. Subsequently, transcript levels of Chk1, Claspin, and E2F1 were determined by quantitative reverse transcriptase-PCR analysis in 103 primary invasive breast carcinomas and were compared with several clinicopathologic variables in breast cancer. A strong correlation was found between Chk1 and Claspin transcript levels. Transcript levels of Chk1, Claspin, and E2F] were highest in histologic grade 3 tumors and in tumors in which the expression of estrogen receptor (ER) and progesterone receptor (PR) was lost. Moreover, Chk1 expression was significantly elevated in grade 3 breast carcinomas showing a triple-negative ER-/PR-/HER-2- phenotype compared with other grade 3 tumors. Further research is warranted to validate the use of Chk1 inhibitors in triple-negative breast carcinomas for which treatment strategies are limited at present.
引用
收藏
页码:6574 / 6581
页数:8
相关论文
共 45 条
[1]   High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses [J].
Abd El-Rehim, DM ;
Ball, G ;
Pinder, SE ;
Rakha, E ;
Paish, C ;
Robertson, JFR ;
Macmillan, D ;
Blamey, RW ;
Ellis, IO .
INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) :340-350
[2]   CELL TURNOVER IN THE RESTING HUMAN-BREAST - INFLUENCE OF PARITY, CONTRACEPTIVE PILL, AGE AND LATERALITY [J].
ANDERSON, TJ ;
FERGUSON, DJP ;
RAAB, GM .
BRITISH JOURNAL OF CANCER, 1982, 46 (03) :376-382
[3]   Basal-like breast carcinomas: clinical outcome and response to chemotherapy [J].
Banerjee, S. ;
Reis-Filho, J. S. ;
Ashley, S. ;
Steele, D. ;
Ashworth, A. ;
Lakhani, S. R. ;
Smith, I. E. .
JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (07) :729-735
[4]   Chk1 and Chk2 kinases in checkpoint control and cancer [J].
Bartek, J ;
Lukas, J .
CANCER CELL, 2003, 3 (05) :421-429
[5]   EGFR gene amplification in breast cancer:: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations [J].
Bhargava, R ;
Gerald, WL ;
Li, AR ;
Pan, QL ;
Lal, P ;
Ladanyi, M ;
Chen, BY .
MODERN PATHOLOGY, 2005, 18 (08) :1027-1033
[6]   Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].
Carey, Lisa A. ;
Perou, Charles M. ;
Livasy, Chad A. ;
Dressler, Lynn G. ;
Cowan, David ;
Conway, Kathleen ;
Karaca, Gamze ;
Troester, Melissa A. ;
Tse, Chiu Kit ;
Edmiston, Sharon ;
Deming, Sandra L. ;
Geradts, Joseph ;
Cheang, Maggie C. U. ;
Nielsen, Torsten O. ;
Moorman, Patricia G. ;
Earp, H. Shelton ;
Millikan, Robert C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502
[7]   Characterization of the 5′Flanking Region of the Human Chk1 Gene Identification of E2F1 Functional Sites [J].
Carrassa, Laura ;
Broggini, Massimo ;
Vikhanskaya, Faina ;
Damia, Giovanna .
CELL CYCLE, 2003, 2 (06) :604-609
[8]   Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics [J].
Chen, Zehan ;
Xiao, Zhan ;
Gul, Wen-zhen ;
Xue, John ;
Bui, Mai H. ;
Kovar, Peter ;
Li, Gaoquan ;
Wang, Gary ;
Tao, Zhi-Fu ;
Tong, Yunsong ;
Lin, Nan-Horng ;
Sham, Hing L. ;
Wang, Jean Y. J. ;
Sowin, Thomas J. ;
Rosenberg, Saul H. ;
Zhang, Haiying .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (12) :2784-2794
[9]   Chk1 is required to maintain Claspin stability [J].
Chini, C. C. S. ;
Wood, J. ;
Chen, J. .
ONCOGENE, 2006, 25 (30) :4165-4171
[10]   Cleavage of claspin by caspase-7 during apoptosis inhibits the Chk1 pathway [J].
Clarke, CAL ;
Bennett, LN ;
Clarke, PR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (42) :35337-35345